DURECT Co. (NASDAQ:DRRX) Receives $27.50 Consensus Target Price from Analysts

DURECT Co. (NASDAQ:DRRXGet Free Report) has received a consensus rating of “Moderate Buy” from the five research firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $27.50.

Several analysts have weighed in on DRRX shares. Oppenheimer reaffirmed an “outperform” rating and set a $5.00 price objective on shares of DURECT in a research report on Monday. HC Wainwright reaffirmed a “neutral” rating on shares of DURECT in a research report on Thursday, March 28th. Finally, StockNews.com raised DURECT from a “sell” rating to a “hold” rating in a research report on Thursday, March 28th.

Read Our Latest Stock Analysis on DRRX

DURECT Stock Performance

DURECT stock opened at $1.15 on Monday. The stock’s 50 day simple moving average is $1.01 and its two-hundred day simple moving average is $1.26. The stock has a market cap of $35.70 million, a price-to-earnings ratio of -0.94 and a beta of 0.85. DURECT has a fifty-two week low of $0.47 and a fifty-two week high of $7.46.

Institutional Trading of DURECT

Hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE boosted its position in shares of DURECT by 5,370.8% in the 1st quarter. Bank of America Corp DE now owns 6,565 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 6,445 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in DURECT by 118.9% in the 1st quarter. Tower Research Capital LLC TRC now owns 6,635 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 3,604 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in DURECT by 38.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,210 shares of the specialty pharmaceutical company’s stock valued at $65,000 after acquiring an additional 3,937 shares in the last quarter. Trexquant Investment LP bought a new position in DURECT in the 2nd quarter valued at approximately $83,000. Finally, Black Diamond Financial LLC bought a new position in DURECT in the 3rd quarter valued at approximately $52,000. 28.03% of the stock is owned by institutional investors.

DURECT Company Profile

(Get Free Report

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.

Recommended Stories

Analyst Recommendations for DURECT (NASDAQ:DRRX)

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.